- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
- Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
- Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
- Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
- Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
- Purple Biotech Reaches Recommended Phase 2 Dose for NT219
- Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
- Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
- Purple Biotech Fortifies NT219 Patent Protection
- Purple Biotech Announces Closing of $5 Million Registered Direct Offering
More ▼
Key statistics
On Thursday, Purple Biotech Ltd (PPBT:NAQ) closed at 0.50, 65.40% above the 52 week low of 0.3023 set on Apr 16, 2024.
52-week range
Open | 0.527 |
---|---|
High | 0.5279 |
Low | 0.5001 |
Bid | 0.3428 |
Offer | 0.65 |
Previous close | 0.5021 |
Average volume | 75.53k |
---|---|
Shares outstanding | 27.40m |
Free float | 26.16m |
P/E (TTM) | -- |
Market cap | 13.29m USD |
EPS (TTM) | -0.8473 USD |
Data delayed at least 15 minutes, as of May 16 2024 20:59 BST.
More ▼